These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 23562171)
21. A non-covalent peptide-based strategy for ex vivo and in vivo oligonucleotide delivery. Crombez L; Morris MC; Heitz F; Divita G Methods Mol Biol; 2011; 764():59-73. PubMed ID: 21748633 [TBL] [Abstract][Full Text] [Related]
22. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Jiang X; Sha X; Xin H; Chen L; Gao X; Wang X; Law K; Gu J; Chen Y; Jiang Y; Ren X; Ren Q; Fang X Biomaterials; 2011 Dec; 32(35):9457-69. PubMed ID: 21911250 [TBL] [Abstract][Full Text] [Related]
23. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Jiang T; Zhang Z; Zhang Y; Lv H; Zhou J; Li C; Hou L; Zhang Q Biomaterials; 2012 Dec; 33(36):9246-58. PubMed ID: 23031530 [TBL] [Abstract][Full Text] [Related]
24. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate. Govindarajan S; Sivakumar J; Garimidi P; Rangaraj N; Kumar JM; Rao NM; Gopal V Biomaterials; 2012 Mar; 33(8):2570-82. PubMed ID: 22192536 [TBL] [Abstract][Full Text] [Related]
25. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells. Dong DW; Xiang B; Gao W; Yang ZZ; Li JQ; Qi XR Biomaterials; 2013 Jul; 34(20):4849-59. PubMed ID: 23541420 [TBL] [Abstract][Full Text] [Related]
26. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma. Shi L; Tang C; Yin C Biomaterials; 2012 Oct; 33(30):7594-604. PubMed ID: 22796165 [TBL] [Abstract][Full Text] [Related]
27. Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel. Hu Q; Gao X; Gu G; Kang T; Tu Y; Liu Z; Song Q; Yao L; Pang Z; Jiang X; Chen H; Chen J Biomaterials; 2013 Jul; 34(22):5640-50. PubMed ID: 23639530 [TBL] [Abstract][Full Text] [Related]
28. Overcoming the polyethylene glycol dilemma via pathological environment-sensitive change of the surface property of nanoparticles for cellular entry. Hama S; Itakura S; Nakai M; Nakayama K; Morimoto S; Suzuki S; Kogure K J Control Release; 2015 May; 206():67-74. PubMed ID: 25770398 [TBL] [Abstract][Full Text] [Related]
30. Modification of calcium carbonate based gene and drug delivery systems by a cell-penetrating peptide. Zhao D; Zhuo RX; Cheng SX Mol Biosyst; 2012 Oct; 8(12):3288-94. PubMed ID: 23086311 [TBL] [Abstract][Full Text] [Related]
31. PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer. Lo YL; Chang CH; Wang CS; Yang MH; Lin AM; Hong CJ; Tseng WH Theranostics; 2020; 10(15):6695-6714. PubMed ID: 32550898 [No Abstract] [Full Text] [Related]
33. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Zheng C; Zheng M; Gong P; Deng J; Yi H; Zhang P; Zhang Y; Liu P; Ma Y; Cai L Biomaterials; 2013 Apr; 34(13):3431-8. PubMed ID: 23375952 [TBL] [Abstract][Full Text] [Related]
34. Multifunctional drug delivery system for targeting tumor and its acidic microenvironment. Shen M; Huang Y; Han L; Qin J; Fang X; Wang J; Yang VC J Control Release; 2012 Aug; 161(3):884-92. PubMed ID: 22587941 [TBL] [Abstract][Full Text] [Related]
35. Peptide based DNA nanocarriers incorporating a cell-penetrating peptide derived from neurturin protein and poly-L-lysine dendrons. Rosli N; Christie MP; Moyle PM; Toth I Bioorg Med Chem; 2015 May; 23(10):2470-9. PubMed ID: 25882529 [TBL] [Abstract][Full Text] [Related]
36. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Han L; Huang R; Liu S; Huang S; Jiang C Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964 [TBL] [Abstract][Full Text] [Related]
37. Tumor microenvironment-specific nanoparticles activatable by stepwise transformation. Ko H; Son S; Jeon J; Thambi T; Kwon S; Chae YS; Kang YM; Park JH J Control Release; 2016 Jul; 234():68-78. PubMed ID: 27164544 [TBL] [Abstract][Full Text] [Related]
38. Cell-penetrating peptide together with PEG-modified mesostructured silica nanoparticles promotes mucous permeation and oral delivery of therapeutic proteins and peptides. Tan X; Zhang Y; Wang Q; Ren T; Gou J; Guo W; Yin T; He H; Zhang Y; Tang X Biomater Sci; 2019 Jun; 7(7):2934-2950. PubMed ID: 31094367 [TBL] [Abstract][Full Text] [Related]
39. Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays. Gao H; Yang Z; Zhang S; Pang Z; Liu Q; Jiang X Acta Biomater; 2014 Feb; 10(2):858-67. PubMed ID: 24239900 [TBL] [Abstract][Full Text] [Related]
40. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Hatakeyama H; Akita H; Kogure K; Oishi M; Nagasaki Y; Kihira Y; Ueno M; Kobayashi H; Kikuchi H; Harashima H Gene Ther; 2007 Jan; 14(1):68-77. PubMed ID: 16915290 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]